Intratumoral CD14+ cells and circulating CD14+HLA-DRlo/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4224-4233

  Gustafson, Michael P ^a   Lin, Yi ^a   Bleeker, Jonathan S ^b   Warad, Deepti ^a   Tollefson, Matthew K ^a   Crispen, Paul L ^c   Bulur, Peggy A ^a   Harrington, Susan M ^d   Laborde, Rebecca R ^a   Gastineau, Dennis A ^a   Leibovich, Bradley C ^a   Cheville, John C ^a   Kwon, Eugene D ^a   Dietz, Allan B ^a  

^a MAYO CLINIC   (United States)

^b Department of Medicine   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CD14 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; HLA ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELLS BY BODY ANATOMY; CLEAR CELL CARCINOMA; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOTHERAPY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; BLOOD; BONE MARROW CELL; COHORT ANALYSIS; CYTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; KIDNEY TUMOR; METABOLISM; METASTASIS; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NORMAL HUMAN; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ANTIGENS, CD14; CARCINOMA, RENAL CELL; COCULTURE TECHNIQUES; COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEALTHY VOLUNTEERS; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MONOCYTES; MYELOID CELLS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PROGNOSIS; TREATMENT OUTCOME;

EID: 84942909842     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0260     Document Type: Article

References (40)

1. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer statistics review, 1975-2012. Bethesda, MD: National Cancer Institute; 2015.
2. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14:6674-82.
3. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1. Transplantation 2002;73:1565-72.
4. Michaelson M, Zhu A, Ryan D, McDermott D, Shapiro G, Tye L, et al. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013;108:1393-401.
5. Tatsugami K, Eto M, Harano M, Hamaguchi M, Miyamoto T, Morisaki T, et al. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma. Int J Urol 2008; 15:694-8.
6. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61.
7. Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, et al. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses. Cancer Immunol Immunother 2009;58:1587-97.
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
9. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9.
10. Bedke J, Stenzl A. Immunologic mechanisms in RCC and allogeneic renal transplant rejection. Nat Rev Urol 2010;7:339-47.
11. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, et al. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer 2013;1:7.
12. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395-400.
13. Dietz AB, Bulur PA, Emery RL, Winters JL, Epps DE, Zubair AC, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 2006;46:2083-9.
14. Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14+HLADRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631-44.
15. Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011;117:872-81.
16. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2010;70:443-55.
17. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in pheripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25: 2546-53.
18. Hoechst B, Ormandy LA, BallmaierM, Lehner F, Kruger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology 2008;135:234-43.
19. Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014;124: 750-60.
20. Poschke I, Mougiakakos D, Hansson J,Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70:4335-45.
21. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044-8.
22. Kusmartsev S, Eruslanov E, Kubler H, Tseng T, Sakai Y, Su Z, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumorinduced immune suppression in renal cell carcinoma. J Immunol 2008; 181:346-53.
23. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60.
24. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinibmediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
25. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012;144:250-68.
26. Gustafson MP, Lin Y, Maas ML, Van Keulen VP, Johnson P, Peikert T, et al. A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans. PLoS One 2015;10:e0121546.
27. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116: e74-e80.
28. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721s-6s.
29. Schmid MC, Varner JA. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010;2010:201026.
30. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. AmJ Pathol 2001;158:735-43.
31. Laborde RR, Lin Y, Gustafson MP, Bulur P, Dietz AB. Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells): the gateway to improved responses. Front Immunol 2014;5:147.
32. Gustafson MP, Lin Y, Ryder M, Dietz AB. Strategies for improving the reporting of human immunophenotypes by flow cytometry. J Immuno Ther Cancer 2014;2:18.
33. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy'in tumor immunobiology and immunotherapy? Immunol Rev 2008;222:222-41.
34. ChittezhathM, DhillonMK, LimJY, Laoui D, Shalova IN, Teo YL, et al. Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. Immunity 2014;41:815-29.
35. Horstmann M, Merseburger A, von der Heyde E, Serth J, Wegener G, Mengel M, et al. Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res and Clin Oncol 2005;131: 715-22.
36. Mokarram N, Bellamkonda RV. A perspective on immunomodulation and tissue repair. Ann Biomed Eng 2014;42:338-51.
37. Doukas J, Blease K, Craig D, Ma CL, Chandler LA, Sosnowski BA, et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol Ther 2002;5:517-27.
38. Zhang Z, Bulur PA, Dogen A, Gastineau DA, Dietz AB. Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLADRlow/neg monocytes mediates chemotherapy resistance. Oncoimmunol 2015;4:e996470.
39. Donskov F. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Dan Med Bull 2007;54:249-65.
40. HermannGG,Geertsen PF, von derMaase H, Zeuthen J. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 1991;34:111-4.